Literature DB >> 8593464

Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties.

K Motoki1, M Morita, E Kobayashi, T Uchida, K Akimoto, H Fukushima, Y Koezuka.   

Abstract

Ten kinds of monoglycosylceramides (MonoCers), having the same ceramide portion and different sugar moieties, were synthesized and their immunostimulatory and antitumor activities were examined. The manner of combination between sugar and ceramide has been demonstrated to affect the manifestation of immunostimulatory and resultant antitumor activities of MonoCers, and in the case of D-MonoCers having the D-sugar, alpha-D-MonoCers (sugar combined to ceramide in an alpha-configuration) show stronger activities than beta-D-MonoCers. Furthermore, the form of sugar, not the furanose-form but the pyranose-form, and the 2"- and 4"-hydroxyl groups of the pyranose-form of sugar, seemed to play an important role in the manifestation of the activities of alpha-D-MonoCers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593464     DOI: 10.1248/bpb.18.1487

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  14 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

2.  Divergent synthetic approach to 6''-modified α-GalCer analogues.

Authors:  Nora Pauwels; Sandrine Aspeslagh; Gerd Vanhoenacker; Koen Sandra; Esther D Yu; Dirk M Zajonc; Dirk Elewaut; Bruno Linclau; Serge Van Calenbergh
Journal:  Org Biomol Chem       Date:  2011-11-01       Impact factor: 3.876

3.  Synthesis and evaluation of 3''- and 4''-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000.

Authors:  Ravinder Raju; Bernard F Castillo; Stewart K Richardson; Meena Thakur; Ryan Severins; Mitchell Kronenberg; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2009-06-06       Impact factor: 2.823

Review 4.  Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Authors:  Philomena Arrenberg; Ramesh Halder; Vipin Kumar
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

Review 5.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

6.  Synthesis and biological activity of alpha-L-fucosyl ceramides, analogues of the potent agonist, alpha-D-galactosyl ceramide KRN7000.

Authors:  Natacha Veerapen; Faye Reddington; Gabriel Bricard; Steven A Porcelli; Gurdyal S Besra
Journal:  Bioorg Med Chem Lett       Date:  2010-04-22       Impact factor: 2.823

Review 7.  The role of natural killer T cells in B cell malignancies.

Authors:  Ghasem Ghalamfarsa; Abolghasem Hadinia; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2013-03-19

Review 8.  The contrasting roles of NKT cells in tumor immunity.

Authors:  Jay A Berzofsky; Masaki Terabe
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

9.  Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.

Authors:  Jessica J O'Konek; Petr Illarionov; Deborah Stewart Khursigara; Elena Ambrosino; Liat Izhak; Bernard F Castillo; Ravinder Raju; Maryam Khalili; Hee-Yong Kim; Amy R Howell; Gurdyal S Besra; Steven A Porcelli; Jay A Berzofsky; Masaki Terabe
Journal:  J Clin Invest       Date:  2011-01-18       Impact factor: 14.808

10.  β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.

Authors:  Jessica J O'Konek; Shingo Kato; Satomi Takao; Liat Izhak; Zheng Xia; Petr Illarionov; Gurdyal S Besra; Masaki Terabe; Jay A Berzofsky
Journal:  Clin Cancer Res       Date:  2013-06-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.